Literature DB >> 27368113

Hb Melusine and Hb Athens-Georgia: potentially underreported in the Belgian population? Four cases demonstrating the lack of detection using common CE-HPLC methods either for glycated hemoglobin (HbA1C) analysis or Hb variant screening.

Bart Peeters1, Inger Brandt2, Koenraad Desmet1, Cornelis L Harteveld3, Davy Kieffer1.   

Abstract

OBJECTIVE AND IMPORTANCE: Suspected hemoglobin (Hb) variants, detected during HbA1C measurements should be further investigated, determining the extent of the interference with each method. CLINICAL
PRESENTATION: This is the first report of Hb Melusine and Hb Athens-Georgia in Caucasian Belgian patients. Intervention & Technique: Since common CE-HPLC methods for HbA1C analysis or Hb variant screening are apparently unable to detect these Hb variants, their presence might be underestimated. HbA1C analysis using CZE, however, alerted for their presence. Moreover, in case of Hb Melusine, even Hb variant screening using CZE was unsuccessful in its detection.
CONCLUSION: Fortunately, carriage of Hb Melusine or Hb Athens-Georgia variants has no clinical implications and, as shown in this report, no apparent difference in HbA1C should be expected.

Entities:  

Keywords:  CE-HPLC; Glycated hemoglobin; Hb Athens-Georgia; Hb Melusine; HbA1C

Mesh:

Substances:

Year:  2016        PMID: 27368113     DOI: 10.1080/17843286.2016.1203559

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  2 in total

1.  Silent hemoglobin variant during capillary electrophoresis: A case report.

Authors:  Yanping Yuan; Xianghai Zhou; Leili Gao; Qian Ren; Linong Ji
Journal:  J Diabetes Investig       Date:  2020-03-18       Impact factor: 4.232

2.  Compound heterozygosity for hemoglobin variant Hb-Broomhill and the Southeast Asian α-thalassemia deletion does not worsen outcome: a case report of two unrelated patients.

Authors:  Danqing Qin; Li Du; Jicheng Wang; Cuize Yao; Hao Guo; Tenglong Yuan; Jie Liang; Aihua Yin
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.